DE-THE-LYCRA-COMPANY
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and textile industry, has announced that its COOLMAX® EcoMade fiber made from 100% textile waste is a key ingredient in the Brazilian Volleyball team’s indoor and beach jerseys for the 2024 Summer Games in Paris. Body Work, a fitness brand from retailer Riachuelo, created the official uniforms unveiled in a stunning projection on the Christ the Redeemer statue overlooking Rio de Janeiro on June 27, Volleyball Day in Brazil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716778680/en/
Body Work, a fitness brand from Riachuelo, has revealed the official Brazilian Volleyball team shirts for the 2024 Summer Games. The fabric blends two technologies from The LYCRA Company: 92% COOLMAX® EcoMade fiber made from pre-consumer textile waste and 8% LYCRA® fiber to help keep athletes cool, dry, and moving freely. (Photo: Business Wire)
COOLMAX® EcoMade fiber transports moisture away from the body to the surface of the fabric, where it evaporates. This helps athletes stay cool, dry, and comfortable so they can focus on the game. It is one of many innovative branded fibers produced by The LYCRA Company designed to help optimize athletic performance. This technology converts pre-consumer textile waste scraps from garment manufacturers into fibers offering comparable performance to virgin polyester.
“We are thrilled that Brazil’s volleyball uniforms feature 92% COOLMAX® EcoMade fiber made from textile waste and 8% LYCRA® fiber, so we will be rooting for them in Paris,” said Nicolas Banyols, chief commercial officer - apparel, The LYCRA Company. “The benefits of activewear and sportswear with performance fibers are not limited to elite athletes anymore. Consumers of all abilities can now buy these innovative garments at retail, ensuring that everyone can experience the enhanced comfort and performance our fibers offer, in addition to options for durable and sustainable fibers for reduced environmental impact.”
LYCRA® brand fibers, now owned by The LYCRA Company, have been an integral part of the games since 1968, when the French alpine ski team dominated the medal count in Grenoble. The team's ski suits featured LYCRA® fiber, which provided a second-skin fit and greater freedom of movement. The long-standing history of performance and innovation in sports is a testament to the trust and reliability that the company’s fibers offer, instilling confidence in athletes and consumers alike.
“While the silver medal-winning 1984 Brazilian volleyball team uniform was the main inspiration for the design of this jersey, we wanted the fabric to be cutting-edge and future-focused,” said Camila de Paula Souza, Style Manager at Body Work | Riachuelo. “This fabric is designed to provide comfort and is made from textile waste—a win for athletes and a win for the planet.”
Consumers may purchase the official Brazilian Volleyball Team shirts at riachuleo.com. For more information on COOLMAX® EcoMade fiber benefits, visit coolmax.com.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
COOLMAX® and LYCRA® are trademarks of The LYCRA Company.
About Riachuelo
With over 75 years of history, Riachuelo operates with the purpose of connecting desires to achievements. By combining innovation, dynamism, and agility to deliver collections and products for all styles, the brand is a leading reference in the sector and is recognized as one of the largest fashion companies in Brazil. Riachuelo boasts more than 30 million cardholders and over 400 own stores across the country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716778680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom